Dr. Chuck Bieberich
Dr. Bieberich received his Ph.D. in Genetics from The Johns Hopkins
University in 1987. Upon completion of his postdoctoral work in
Developmental Genetics at Yale University, he was appointed as a
Scientist at the Holland Laboratory of the American Red Cross in 1990,
with a joint appointment in the Department of Biochemistry at George
Washington University School of Medicine.
Dr. Bieberich’s early research focus was on body plan evolution, using
the mouse as a model system. His work revealed a critical role for
Hox genes in shaping the axial skeleton, and showed that modern
mammals still have the potential to generate body forms that have been
absent for hundreds of millions of years. His evolutionary studies
were published in Cell, the Proceedings of the National Academy of
Sciences, and featured on the cover of The New Scientist, and in the
Dallas Morning News.
In 1996, Dr. Bieberich’s lab reported the discovery of a new mouse
developmental gene called Nkx3.1 that plays a role prostate gland
organogenesis. Subsequent studies by Dr. Bieberich and many others
have shown that the human counterpart of this gene is a critical
“gatekeeper” prostate tumor suppressor gene.
In 1997, Dr. Bieberich moved his lab to the Department of Biological
Sciences at UMBC, where he continues to study the biology and
biochemistry of Nkx3.1 and other proteins in prostate development and
disease. His recent works, focusing on post-translational regulation
of NXK3.1 lead his team to develop a powerful new assay to identify
substrates of protein kinases, for which two US patents have been
awarded. In collaboration with a group at John Hopkins University
School of Medicine, Dr. Bieberich’s lab has developed cutting-edge
mouse models of lethal forms of human prostate cancer as well as other
mouse models of benign prostate disease.
His ongoing work is focused on leveraging the expertise of his team in
kinase biology and disease modeling to develop new therapeutic
approaches to treat prostate cancer. Dr. Bieberich’s lab has received
continuous federal funding since 1992 from the National Institutes of
Health and the Congressionally Directed Medical Research Program
(CDMRP). He is currently funded by the National Cancer Institute, the
National Institute for Diabetes, and Digestive, and Kidney Diseases
(NIDDK), and the Patrick C. Walsh Prostate Cancer Research Fund.
In addition, Dr. Bieberich also has a longstanding interest in
increasing diversity in the biomedical research community, and has
received the Meyerhoff Mentor of the Year Award. He has served since
2003 as the Program Director of the NIDDK-supported Short-Term
Education Program for Underrepresented Persons, which funds the UMBC
Biomedical Summer Undergraduate Research Experience training program.
Dr. Bieberich has also served on numerous grant review study sections
for both the NIH and the CDMRP, and is currently on the Scientific
Advisory Board of the Center for Prostate Disease Research in